{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33097915",
  "DateCompleted": {
    "Year": "2021",
    "Month": "01",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "07",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/s41571-020-00446-0"
    ],
    "Journal": {
      "ISSN": "1759-4782",
      "JournalIssue": {
        "Volume": "18",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "Nature reviews. Clinical oncology",
      "ISOAbbreviation": "Nat Rev Clin Oncol"
    },
    "ArticleTitle": "Consequences of COVID-19 for cancer care - a CRUK perspective.",
    "Pagination": {
      "StartPage": "3",
      "EndPage": "4",
      "MedlinePgn": "3-4"
    },
    "Abstract": {
      "AbstractText": [
        "We reflect on the past 10 months of clinical activity in oncology in the UK during the COVID-19 pandemic and suggest how services can be protected during subsequent waves of infection."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cancer Research UK, Redman Place, London, UK."
          }
        ],
        "LastName": "Greenwood",
        "ForeName": "Emma",
        "Initials": "E"
      },
      {
        "Identifier": [
          "0000-0002-4299-3018"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cancer Research UK, Redman Place, London, UK. Charles.Swanton@crick.ac.uk."
          },
          {
            "Identifier": [],
            "Affiliation": "Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Charles.Swanton@crick.ac.uk."
          },
          {
            "Identifier": [],
            "Affiliation": "Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. Charles.Swanton@crick.ac.uk."
          }
        ],
        "LastName": "Swanton",
        "ForeName": "Charles",
        "Initials": "C"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Nat Rev Clin Oncol",
    "NlmUniqueID": "101500077",
    "ISSNLinking": "1759-4774"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [
        "methods",
        "statistics & numerical data",
        "trends"
      ],
      "DescriptorName": "Biomedical Research"
    },
    {
      "QualifierName": [
        "epidemiology",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Epidemics"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods",
        "statistics & numerical data",
        "trends"
      ],
      "DescriptorName": "Medical Oncology"
    },
    {
      "QualifierName": [
        "diagnosis",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "isolation & purification",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "United Kingdom"
    }
  ],
  "CoiStatement": "C.S. receives grant support from Archer Dx, AstraZeneca, Boehringer\u2013Ingelheim and Ono Pharmaceutical; has consulted for AstraZeneca, Bicycle Therapeutics, Celgene, Genentech, GRAIL, GSK, Illumina, Medicxi, MSD, Novartis and the Sarah Cannon Research Institute; receives grant support and has consulted for Bristol Myers Squibb, Pfizer and Roche\u2013Ventana; is an advisory board member and is involved in trials sponsored by AstraZeneca; has stock options in Apogen Biotech-nologies, Epic Bioscience, GRAIL; and has stock options and is a co-founder of Achilles Therapeutics. E.G. declares no competing interests."
}